PharmaTimes3d
Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
PharmaTimes3d
Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol
Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol for ...
PharmaTimes4d
AstraZeneca receives positive recommendations for lung cancer treatments
AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...
PharmaTimes4d
Innovative Health Initiative launches a trial aimed at ending Crohn’s Disease
This initiative, funded by the Innovative Health Initiative Joint Undertaking (IHI JU) with over EUR 38 million, aims to ...
PharmaTimes5d
AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025
AlzeCure Pharma AB announced that its abstract on NeuroRestore ACD856 has been accepted for presentation at the AD/PD 2025 ...
PharmaTimes5d
EC approves lazertinib in combination with amivantamab for NSCLC patients
The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...